Actively Recruiting
Immediate Chemotherapy Following Resection for High-Risk Non-Muscle-Invasive Bladder Cancer
Led by Changhai Hospital · Updated on 2025-03-21
72
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Residual tumors after transurethral resection of bladder tumors (TURBT) range from 17-70%, and floating tumor cells from traditional segmental resection may lead to recurrence if they re-implant in the bladder wall. Immediate systemic chemotherapy post-surgery aims to eliminate microlesions promptly and minimize recurrence risk, yet its safety and efficacy require further exploration. This prospective, single-arm study delves into evaluating the efficacy and safety of immediate postoperative systemic chemotherapy in patients with suspected high-risk non-muscle-invasive bladder cancer.
CONDITIONS
Official Title
Immediate Chemotherapy Following Resection for High-Risk Non-Muscle-Invasive Bladder Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with a history and cystoscopy results indicating high-risk NMIBC, including high-grade T1, any recurrent high-grade Ta, high-grade Ta with tumor diameter greater than 3 cm or multifocal, any carcinoma in situ (CIS), any Bacillus Calmette-Gu9rin (BCG) failure in patients with high-grade disease, any variant histology, any lymphovascular invasion (LVI), and any high-grade prostatic urethral involvement
- Patients in generally good condition with a follow-up period of 2 years
You will not qualify if you...
- Bladder cancer other than urothelial carcinoma (UC)
- Muscle-invasive bladder cancer (MIBC) or benign diseases
- Incomplete tumor resection
- Active infection
- Concurrent upper urinary tract or prostatic urethral urothelial carcinoma (UC)
- Previous systemic chemotherapy, immunotherapy, or radiotherapy
- Leukopenia or thrombocytopenia
- Serum creatinine greater than twice the normal level
- Uncontrollable urinary tract infection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai Changhai Hospital
Shanghai, Shanghai Municipality, China, 200000
Actively Recruiting
Research Team
S
Shuxiong Zeng, M.D. Ph.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here